After TSX debut, B.C. biotech champion Eupraxia targets human trial for new drug

VANCOUVER — When Victoria-based Eupraxia Pharmaceuticals completed its initial public offering last month, it was the first Canadian biotech company in 18 years to list its shares solely on the Toronto Stock Exchange. Despite the nearly two-decade long drought, Eupraxia’s founders believed Canada’s investor community would support its offering. Canadian investors and the government had already bought in—to the tune of tens of millions of dollars—to the company’s technology, which offers a way to deliver drugs to a specific spot in the body and release them slowly.

“Sure enough, we found that our story resonated, that people understood both our lead asset, as well as the platform potential that we had,” said chief executive and co-founder James Helliwell in an interview with The Logic, his first since taking the company public. That support came, even though “at the time we were doing the IPO, the market itself was having a few little hiccups.”

Helliwell believes that timing is why the company raised $9 million less than initially planned, but still enough to fund a human trial for its technology’s lead candidate: a treatment that offers relief for knee pain from osteoarthritis.

    Join now to start reading premium, award-winning journalism.

    By entering your e-mail you consent to receiving commercial electronic messages from The Logic Inc. containing news, updates, offers or promotions about The Logic Inc.’s products and services. You can withdraw your consent at anytime. Please refer to our privacy policy or contact us for more details.

    In-depth, agenda-setting reporting

    Great journalism delivered straight to your inbox.


    Amazon scales back U.S. warehouse expansion plans

    Enthusiast Gaming faces revolt from largest shareholder

    Canada not part of new U.S.-led Asian-Pacific economic bloc

    Best business newsletter in Canada

    Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.

    Exclusive events

    See the bigger picture with reporters and industry experts in subscriber-exclusive events.

    Membership in The Logic Council

    Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.

    Canada's most influential executives and policymakers are reading The Logic

    • CPP Investments
    • Sun Life Financial
    • C100
    • Amazon
    • Telus
    • Mastercard
    • bdc
    • Shopify
    • Rogers
    • RBC
    • General Motors
    • MaRS
    • Government of Canada
    • Uber
    • Loblaw Companies Limited